Literature DB >> 27246829

Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy.

Kieu-Suong Le1, Marie-Laure Thibult2, Sylvain Just-Landi3, Sonia Pastor4, Françoise Gondois-Rey4, Samuel Granjeaud4, Florence Broussais3, Reda Bouabdallah3, Renaud Colisson5, Christophe Caux5, Christine Ménétrier-Caux5, Dominique Leroux6, Luc Xerri7, Daniel Olive8.   

Abstract

The prognosis of follicular lymphoma (FL) patients is suspected to be influenced by tumor-infiltrating regulatory T cells (Treg). The mechanism of Treg enrichment in FL and their impact on malignant FL B cells remains to be elucidated. We analyzed 46 fresh lymph node biopsy samples, including FL (n = 20), diffuse large B-cell lymphoma (n = 10), classical Hodgkin lymphoma (n = 9), and reactive lymphadenitis (n = 7). Using multicolor flow cytometry and cell sorting, we observed an accumulation of CD25(high)CD127(low/neg) Tregs in FL tissues. These Tregs comprised activated ICOS(+) Tregs that were able to suppress not only conventional T cells, but also FL B cells. These FL B cells were able to express ICOSL in vitro and to generate CD25(high)FoxP3(high) Tregs expressing ICOS. Treg generation was associated with ICOS/ICOSL engagement and was abrogated by antagonist anti-ICOS and anti-ICOSL antibodies. Interactions between Tregs and FL B cells resulted in ICOSL downregulation on FL B cells. Our results highlight a key role for Tregs in FL pathogenesis and suggest that targeting the ICOS/ICOSL pathway may be a promising immunotherapy for FL treatment. Cancer Res; 76(16); 4648-60. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27246829     DOI: 10.1158/0008-5472.CAN-15-0589

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Role of the microenvironment across histological subtypes of NHL.

Authors:  Karin Tarte
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 2.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

Review 3.  T follicular helper cells in germinal center B cell selection and lymphomagenesis.

Authors:  Michelle A Mintz; Jason G Cyster
Journal:  Immunol Rev       Date:  2020-05-15       Impact factor: 12.988

4.  MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells.

Authors:  Zhong Zheng; Peng-Peng Xu; Li Wang; Hui-Jin Zhao; Xiang-Qin Weng; Hui-Juan Zhong; Bin Qu; Jie Xiong; Yan Zhao; Xue-Feng Wang; Anne Janin; Wei-Li Zhao
Journal:  J Exp Clin Cancer Res       Date:  2017-06-21

Review 5.  Reviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment.

Authors:  Tim Both; Virgil A S H Dalm; P Martin van Hagen; Paul L A van Daele
Journal:  Int J Med Sci       Date:  2017-02-23       Impact factor: 3.738

Review 6.  Herpesviruses dUTPases: A New Family of Pathogen-Associated Molecular Pattern (PAMP) Proteins with Implications for Human Disease.

Authors:  Marshall V Williams; Brandon Cox; Maria Eugenia Ariza
Journal:  Pathogens       Date:  2016-12-28

7.  Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells.

Authors:  Yixiang Han; Yuqing Dong; Qianqian Yang; Wanling Xu; Songfu Jiang; Zhijie Yu; Kang Yu; Shenghui Zhang
Journal:  Front Immunol       Date:  2018-09-26       Impact factor: 7.561

8.  A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system.

Authors:  Aude Burlion; Rodrigo N Ramos; Pukar Kc; Kélhia Sendeyo; Aurélien Corneau; Christine Ménétrier-Caux; Eliane Piaggio; Daniel Olive; Christophe Caux; Gilles Marodon
Journal:  Oncoimmunology       Date:  2019-04-12       Impact factor: 8.110

9.  ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.

Authors:  Florent Amatore; Nicolas Ortonne; Marc Lopez; Florence Orlanducci; Rémy Castellano; Saskia Ingen-Housz-Oro; Amandine De Croos; Clémentine Salvado; Laurent Gorvel; Armelle Goubard; Yves Collette; Réda Bouabdallah; Jean-Marc Schiano; Nathalie Bonnet; Jean-Jacques Grob; Philippe Gaulard; Martine Bagot; Armand Bensussan; Philippe Berbis; Daniel Olive
Journal:  Blood Adv       Date:  2020-10-27

Review 10.  The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.

Authors:  Takashi Watanabe
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.